INTRODUCTION
Leprosy and tuberculosis, continue to be public health concern in many countries around the world. World Health Organization (WHO, 2010a) estimated that there were over 244 000 reported cases globally in 2009. Due to the resistance of most strains of M. leprosy and M. tuberculosis, the treatment of leprosy has changed in the past three decades. Dapsone monotherapy was replaced by multidrug therapy (with dapsone, rifampicin and clofazimine) in 1982 (WHO, 1982; Gautam, 2009 ). Since its introduction, multidrug therapy has been an important tool in leprosy elimination; not only has it helped to reduce the duration of treatment but it has also been useful in addressing problems related to resistance to dapsone and relapses (Gautam, 2009; Visschedijk et al., 2000; Meima et al., 2004) . Thus, there has been a renewed effort to find newer regimens that may shorten the duration of therapy and improve compliance while simultaneously maintaining or improving the therapeutic advantages of previous regimens (Sehgal et al., 2008; Maninder et al., 2011) .
Isoniazid (INH) has remained one of the first line drugs for the treatment of tuberculosis and leprosy since its discovery. It is highly effective against mycobacteria for which its minimal tuberculostatic concentration is 0.025-0.5mcg/ml whereas concentrations of over 500mcg/ml are required to inhibit the growth of other microorganisms (Dorthe et al., 1995) .
Fluoroquinolones represent a class of antimicrobials which has gained popularity because of their very impressive pharmacokinetics properties, efficacy, convenient oral dosage schedule, broad-spectrum anti-microbial activity and low incidence of adverse reactions (Goel et al., 1998; Walker et al., 1991; Wolfson and Hooper, 1991a; Kumar and Gurumurthy, 2004, EMEA/CVMP/SAGAM, 2004; O'Brien et al., 2012) . Ofloxacin, is a synthetic analogue of nalidixic acid which inhibit the bacterial enzyme
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DNA gyrase that is responsible for the control of the super coiling of the bacterial DNA; ofloxacin is also responsible for the continuous introduction of negative super coils into DNA (Diver, 1998; WHO, 1998a; Guay, 1992a) . It precipitates seizure in epileptics and also causes arthropathy in young (WHO, 1998b) . Drug combination therapy including ofloxacin and isoniazid have been employed in the management of mycobacterial infections.
The determination of drug concentrations in the saliva and urine has gained widespread acceptance in a variety of settings (Drobitch and Svensson, 1992) . The estimation of drugs in the saliva and urine has been employed for therapeutic drug monitoring, effectiveness of the excretory organs and for calculation of pharmacokinetic variables (Mucklow, 1982) . The rational use of such determinations can provide knowledge of patient-specific pharmacokinetic parameters leading to improved therapy (Spectar et al., 1988) . Saliva and urine can serve as an alternative body fluid for pharmacokinetic investigations. It can be collected with minimal patient discomfort and can be easily obtained on multiple occasions. It is particularly suitable for investigations in geriatrics and pediatrics. Pharmacokinetic studies have shown that ofloxacin penetrates into saliva and its concentration correlates well with serum levels (Guay, 1992b ).
The present study was undertaken to evaluate the pharmacokinetics of isoniazid (INH) in saliva, plasma and urine when administered alone or in combination with other antimycobacterial drugs ofloxacin (OXC). We have also attempted to calculate the saliva-plasma ratio of INH.
MATERIALS AND METHODS

Study participant
Five healthy subjects aged between 18 and 39 years and weight range between 50-83Kg participated in the study after an informed consent. The subjects were assessed to be healthy on the basis of medical history, hepatic and renal function tests. None of the subjects was taking any medication one week before or during the study for any ailment and were nonalcoholics. The study protocol was approved by the Institutional Ethics Committee and written informed consent was obtained from all the volunteers.
Study design
In phase one (INH alone), each subject initiated the study after an overnight fast. One 300mg tablet (usual adult dose) of INH was administered orally with about 350ml of water. Food was restricted for 2 hours after commencement. Blood and saliva samples were collected at 0 hr (i.e. just before taken INH) then half hourly until 8th hour then at 12th and 24th hour. Urine samples were also collected at zero hour, then hourly until the 8th hour, then at 12th hour, 24th hour and finally at 48th hour. The same procedure was followed for phase two (INH + OXC) after a one-week drug wash-out period and the drug administered (orally) to the subject was 300mg of INH and 200mg film coated OXC tablets and all the samples collected as in phase one (INH alone).
Sample collection and handling
The total volume of urine voided at each occasion was recorded and 10ml of the urine was withdrawn and placed in a test tube. The pH of the urine samples was estimated using pH meter. One millilitre of toluene was added to the urine and stored frozen at -20°C until analysis. About 3ml of saliva was collected at the predetermined time intervals and the pH of the samples was estimated as stated for the urine samples. The test tubes of the saliva were stored frozen at -20°C until analyzed.
Blood samples were collected through indwelling butterfly (scalp vein) needles kept patent with heparinized normal saline. The heparinized saline was withdrawn with a syringe prior to each blood sample collection. About 4ml of blood sample was collected and placed in EDTA containing test tubes pending the separation of the plasma. Blood samples were centrifuged and only the plasma collected and stored frozen at -20°C until analyzed.
Sample analysis
The spectrophotometric method of Bjornesjo and Jarnuff (Bjornosjo and Jarnuff, 1967) was used with slight modification in the assay of INH in saliva and urine samples, while plasma INH concentration was analyzed using the Ehrlich's reagent. About 1 ml of 2M acetic acid and 1ml of chromogenic reagents freshly prepared from equal volume of 2% sodium nitroprusside and 4M NaOH was added to 2 ml of urine. The mixture was vortexed and absorbance
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read after 2 minutes against a urine blank at 445nm in the spectrophotometer (UV-Visible SP6 Pye Unicam).
The same procedure was carried out for saliva samples and the absorbance read at 445nm against saliva blank in the spectrophotometer (UV-Visible SP6 Pye Unicam). One millilitre Ehrlich's reagent was added to one millilitre of plasma. This was vortex mixed and a one in ten dilution of the resultant turbid solution was read against the plasma blank at 445 nm in a spectrophotometer. Calibration curve for Beer's plot was obtained using INH concentration of 12, 6, 3, 1.5, 0.75 mcg/ml.
Pharmacokinetic analysis
To analyze the INH concentration data we assumed a one compartment open model with linear kinetics. The concentration-time data for each study period 1-24h after completion of rifampicin administration were fitted by a non-linear least squares regression to the following equation, C=C0.e -(kt) where C is the concentration at time t and C0 is the concentration when t = 0. The elimination half life (t½e) was calculated from the elimination rate constant (K) by the formula 0.693/K. The area under the serum concentration time curve (AUC) was calculated from 0 to 24h by the trapezoidal rule and was extrapolated to infinity by adding the INH concentration at 24h divided by K (Wagner, 1975) . The volume of distribution (Vd) was calculated for each treatment by dividing the dose of INH by the initial serum concentration of INH when t is equal to zero. The total body clearance (Cl) with or without administration of ofloxacin was obtained by multiplying Vd by the quantity 0.693 divided by the serum half-life (Vd×0.693/K) (Gibaldi and Perrie, 1975) . Renal clearance (Clr) of INH was calculated by dividing the amount of INH recovered in urine by the AUC for serum concentrations versus time from 12 -24h. The method of residuals was used to determine the absorption rate (Ka), while the concentration maximum (Cmax) and the corresponding time (Tmax) were read off from the serum concentration versus time curve. The mean absorption time (MAT) was calculated from the reciprocal of Ka (1/Ka). The amount of INH excreted or recovered in urine was calculated using the method of Ritschel (Ritschel 1980) . The saliva/plasma concentration ratio was calculated using the mean AUC's as described by Eatman et al., (1977) (Mean saliva AUC/Mean plasma AUC).
Statistical analysis
The differences between two related samples were analyzed using Student's t-test (paired). Differences were considered statistically significant at p < 0.05 (two tailed). Data are expressed as mean ± SD.
RESULTS
The amount of plasma INH absorbed (AUC) was non-significantly reduced from 65.50mcg/ml/h (INH alone) to 59.60mcg/ml/h (INH + OXC) but significantly increased in saliva data 8.96 (INH alone) and 9.35mcg in INH + OXC (Table1). The plasma Cmax of Table 2 ).
The mean amount and percentage of INH excreted with or without OXC are presented as bar chart in Figure 1 , also presented as bar chart is the plasma and saliva Cmax with or without OXC (Figure 2 ). Mean INH concentrations (mcg/ml) time curves in both plasma and saliva with and without OXC are shown in figure 3 . From the figure, the peak INH concentration (Cmax) occurred at 1.5 h, while the presence of OXC shifted the Tmax to 2h. Measurable INH concentration was obtained up to the 12 th hour. The figure indicates a non-significant effect of OXC on plasma and saliva curve of INH. The concentrations of INH in saliva were much lower than those in plasma as evidenced from Figure 3 . Figure 4 shows the graph of the cumulative INH excreted in the Urine versus time with and without OXC, the excretion was almost same within the first 7 hours, after which the excretion assumed almost a plateau with OXC causing more excretion of INH than the control. It is evident that the rate of excretion of INH (excretion per hour) was almost the same with or without OXC as shown in Figure 5 .
DISCUSSION
The effect of ofloxacin on the pharmacokinetics profile of INH after oral administration in man, has been investigated. INH has proved to be a valuable addition to the available anti-TB drugs with a MIC of 1.0 mg/ml against Mycobacterium tuberculosis. Although it is metabolized by acetylation, by the hepatic enzyme acetyl transferase, it is largely (Kazung 1982 ) . In fast acetylators, the t½ of INH is 1-1.5h whereas for slow acetylators, the t½ of INH is about 3h (Schild 1980) . The established Tmax of INH is 1-2h and the plasma Cmax is 3-5mcg/ml (Schild, 1980; Jain, 1998) .
The results of this study show that ofloxacin increased the rate of absorption (both Tmax and Cmax) of INH but reduced the extent of absorption (AUC).
In an earlier study on the effect of ciprofloxacin, another fluoroquinolones, on INH, the presence of ciprofloxacin led to an increase in the amount of INH absorbed but caused a slight reduction in the Cmax of INH (Ofoefule et al., 2001 ) . This is attributed to the fact that ciprofloxacin as reported earlier is an inhibitor of cholinergic neurotransmission leading to an inhibition of gastric motility and emptying (Tamaoki, 1995) . This may also be attributed to the fact that, all fluoroquinolones preparations may not exhibit exactly the same pharmacokinetic behavior owing to differences in their formulation additives and the manufacturers involved in the production of the various tablets.
When isoniazid was administered in combination with ofloxacin, there were little or no variations in the pharmacokinetic parameters calculated based on the salivary and plasma estimates. This could be due to the small sample size in this group (n=5) and inter-individual differences in the absorption and metabolism of the drug. Ofloxacin reduced the volume of distribution of INH, this variation in Vd of INH owing to the co-administration of ofloxacin with INH is of doubtful clinical significance being statistically insignificant. Ofloxacin increased the urinary excretion of INH compared to the control which may be due to its increase in the absorption rate and the overall bioavailability of INH, it could be that the higher level of INH in the blood made for the greater excretion of INH in the urine. It has been reported earlier that other fluoroquinolones also increase the urinary excretion of INH (Orisakwe et al., 2004) . The mean INH excretion in urine versus time graphs assumed the form of a plateau in each phase with ofloxacin giving higher values than the control. The excretion profile of INH was almost same in the two phases signifying that ofloxacin does not affect the rate of INH plasma excretion.
From the saliva data, ofloxacin increased the rate of absorption of INH. This is in harmony with the conclusion drawn from the plasma data that INH Cmax and AUC in saliva were less than what were obtained in plasma in the two phases. This scenario also conforms to the findings obtained for some other drugs by other researchers (Kumar and Gurumurthy, 2004) . Using saliva instead of blood for pharmacokinetic investigations has obvious practical advantages. It is a painless, non-invasive procedure, hence suitable for the collection of multiple specimens. Variable results have been reported for the ratio of saliva to serum concentrations. Koizumi et al. (1994) reported a ratio of 1.0 between 2-8 h after administration of a 300 mg dose. Fujita et al. (1995) in their studies on patients with renal impairment had reported a ratio of 1:1 for saliva to serum concentrations. However, Warlich et al. (1990) have reported a ratio of 0.6 and a close relation of levels in the saliva and serum (r= 0.99), which is consistent with our findings. The mean saliva/plasma (S/P) ratio of ofloxacin was around 0.6 and this remained the same when ofloxacin was given in any combination. From this study, the mean saliva plasma concentration ratio using the mean AUC's as described by Eatman et al. (1977) gave the mean INH saliva plasma ratio of 0.14 in control and 0.16 with ofloxacin. The S/P ratio is a possible measure of the amount of protein binding to the drug. There was a good correlation (0.94) with respect to drug concentrations. The pharmacokinetic parameters such as Cmax, tmax, AUC, and t½ of isoniazid did not change when given in combination with other anti-TB drugs suggesting that the pharmacokinetics of isoniazid are not affected or altered when administered with the other anti-TB drugs, however, synergistic or additive effect may be seen when used in multiple drug therapy. There was no pH alteration observed in both urine and saliva sample from pH determination both at the collection and just before the analysis.
CONCLUSION
The present study shows that several pharmacokinetic parameters can be calculated using salivary concentrations of INH as can be done with plasma. The estimation of INH levels in saliva seems to be useful in therapeutic drug monitoring and pharmacokinetic studies. Based on the salivary levels, the present study compares the pharmacokinetic parameters of isoniazid when given alone and in combination with ofloxacin.
Further investigations are required to determine whether the concentration of isoniazid in saliva can act as a valid index after multiple dosing. 
